Clinical Trial of Growth Hormone in MPS I, II, and VI

Inclusion Criteria: * A parent or legally authorized representative must provide written informed consent and comply with study assessments for the full duration of the study. * Chronologic age ≥ 5 years and bone age ≤12 years * Diagnosis of MPS I, II, or VI * Height ≤ -2 SDS for age and gender * Ability to travel to study center for evaluations. * Ability of the participant to cooperate with study procedures, to notify a guardian of symptoms, and provide assent for participation in the study. Exclusion Criteria: * History of treatment with hGH * Untreated pituitary deficiency * Pregnancy (positive urine pregnancy test) prior to enrollment in the study * Participation in another simultaneous medical intervention trial * Patients with closed epiphysis * Active neoplasm * Orthopedic procedure of the femur within the last 6 months. * Known or suspected allergy to trial product or related products. * Structural lesion on brain MRI resulting in brain compression * Any other social or medical condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated or be detrimental to the study. * Obstructive sleep apnea without BiPAP or tonsillectomy/adenoidectomy treatment. * CNS shunt. * Abnormal cardiac function based on echocardiogram within 6 months prior to enrollment : * Ejection fraction less than 50% * Left ventricular chamber size greater than or less than 2 standard deviations of normal for body surface are…